Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Purchase Molecular Probes for $325M

NEW YORK, July 2 - Carlsbad, Calif.-based Invitrogen today announced the purchase of privately-held Molecular Probes of Eugene, Ore., in a $325 million cash transaction expected to close in the third quarter.

 

The acquisition brings together Invitrogen, a genomic research reagents, software and service provider with 28-year-old Molecular Probes, a provider of fluorescence-based technologies. With a market capitalization of nearly $2 billion, Invitrogen reported revenues of $181 million for the third quarter ending March 31.

 

Molecular Probes, founded in 1975, had revenues of $56 million in 2002, Invitrogen said.

 

With the sale, Invitrogen is aiming to position itself in the drug discovery and development sector, Greg Lucier, the company's CEO said in a statement.

 

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.